Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab Beta + Pucotenlimab + Chemotherapy as Neoadjuvant Therapy for KRAS/NRAS Wild-Type Left-Sided Colon and Upper Rectal Cancer
ChiCTR2500110202Phase 2Not yet recruiting
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab and pucotenlimab in colorectal cancer (CRC), colon cancer and rectal cancer, sponsored by The First Hospital of Fujian Medical University. Primary endpoint: Major pathological response rate. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
cetuximabpucotenlimab
03
Conditions
colorectal cancer (CRC)colon cancerrectal cancer
Beyond the preview
Go deeper on ChiCTR2500110202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110202.